What happened
Graph AI, a company that has developed the AI-native pharmacovigilance platform Graph Safety, has announced a $13.3 million Series A funding round led by Insight Partners, with participation from existing investor Bessemer Venture Partners. The company plans to use the funding to accelerate its expansion across the United States and Europe.
Graph AI has developed the AI-native pharmacovigilance platform Graph Safety, which combines AI with deterministic controls, validation layers, and end-to-end audit trails designed for regulated pharmacovigilance environments.
The platform has been designed with reference to applicable regulatory requirements and evolving expectations for AI in medicines development and patient safety.
In live deployments, Graph Safety has reduced case processing turnaround time from more than three hours to under 10 minutes, a reduction of more than 90 per cent, and lowered operating costs by up to 66 per cent.
Since raising its seed round in October 2025, Graph AI has brought two modules to market: Intake, which captures and triages incoming adverse-event reports across every channel, and Nucleus, an intelligent safety database that automates case processing end to end.
A third module, called Report, for automated aggregate reporting, is also launching this month.
Source details: business-standard.com
Why it matters
The funding round is significant for Graph AI as it will enable the company to expand its operations and reach more customers. The company's AI-native pharmacovigilance platform, Graph Safety, has been designed to reduce case processing turnaround time and lower operating costs for pharmaceutical and biotech companies.
The funding round is significant for Graph AI as it will enable the company to expand its operations and reach more customers.
The company's AI-native pharmacovigilance platform, Graph Safety, has been designed to reduce case processing turnaround time and lower operating costs for pharmaceutical and biotech companies.
The platform's ability to reduce case processing turnaround time and lower operating costs has the potential to significantly impact the pharmaceutical and biotech industries.
The company's plans to expand its operations in the United States and Europe will enable it to reach more customers and increase its revenue.
The funding round will also enable the company to continue to develop and improve its AI-native pharmacovigilance platform.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
A route planner searches possible journeys using explicit rules. What does this illustrate about AI?
What to watch next
The company's plans to expand its operations in the United States and Europe, and the potential impact of its AI-native pharmacovigilance platform on the pharmaceutical and biotech industries.
The company's plans to expand its operations in the United States and Europe.
The potential impact of its AI-native pharmacovigilance platform on the pharmaceutical and biotech industries.
The company's ability to continue to develop and improve its AI-native pharmacovigilance platform.
The company's plans to launch a third module, called Report, for automated aggregate reporting.
The company's plans to onboard more pharmaceutical and biotech customers.